Activation of Angiotensin-Converting Enzyme 2 Mitigates Gastrointestinal Acute Radiation Syndrome.

ABSTRACT:

Purpose

In a radiation mass casualty event, exposed populations will suffer dose-dependent toxicity to multiple organ systems. Although several therapies are US Food and Drug Administration-approved for treatment of the hematopoietic acute radiation syndrome (ARS), there are no US Food and Drug Administration-approved medical countermeasures for either acute gastrointestinal (GI) injury or multiorgan delayed effects of acute radiation exposure (DEARE). Prior data suggest activation of the alternative renin angiotensin system (RAS) enzyme angiotensin-converting enzyme 2 (ACE2) has therapeutic potential for mitigating multiorgan radiation injury, including GI-ARS. Here, we evaluated whether activation of ACE2 mitigates GI-ARS in rodent models and protects against DEARE in GI-ARS surv

SUBMITTER: Sharma GP 

PROVIDER: S-EPMC12797870 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature